Recognition | I3H MODX Implementation | Perelman School of Medicine at the University of Pennsylvania

Michael Cancro (1949–2025)

Mark J. Shlomchik and David Allman - Immunity 58, April 8, 2025 PMID is: 40203802

Grant Awarded to Advance Gastroesophageal Cancer Treatment

The DeGregorio Family Foundation, with additional support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative, awarded Saar Gill, MD, PhD, an associate professor of Hematology-Oncology, a $450,000 grant to continue work on his “Trojan horse” immunotherapy targeting...

Celiac disease

Drew Weissman and Jilian Melamed of the Perelman School of Medicine are leading research into how to use mRNA therapies to treat or even prevent celiac disease. “I got into medicine to help people, and it makes me feel good...

Continuous expression of TOX safeguards exhausted CD8 T cell epigenetic fate.

Huang YJ, Ngiow SF, Baxter AE, Manne S, Park SL, Wu JE, Khan O, Giles JR, Wherry EJ. Sci Immunol. 2025 Mar 7;10(105):eado3032. doi: 10.1126/sciimmunol.ado3032. Epub 2025 Mar 7. PMID: 40053604

Tick feeding or vaccination with tick antigens elicits immunity to the Ixodes scapularis exoproteome in guinea pigs and humans.

Hart TM, Cui Y, Telford SR, Marín-López A, Calloway K, Dai Y, Matias J, DePonte K, Jaycox J, DeBlasio M, Hoornstra D, Belperron AA, Cibichakravarthy B, Johnson EE, Alameh MG, Dwivedi G, Hovius JWR, Bockenstedt LK, Weissman D, Ring...

Assessing the oncogenic risk: the long-term safety of autologous chimeric antigen receptor T cells.

Baker DJ, Levine BL, June CH. Lancet. 2025 Mar 1;405(10480):751-754. doi: 10.1016/S0140-6736(25)00039-X. PMID: 40023653

Immune targeting and host-protective effects of the latent stage of Toxoplasma gondii.

Eberhard JN, Shallberg LA, Winn A, Chandrasekaran S, Giuliano CJ, Merritt EF, Willis E, Konradt C, Christian DA, Aldridge DL, Bunkofske ME, Jacquet M, Dzierszinski F, Katifori E, Lourido S, Koshy AA, Hunter CA. Nat Microbiol. 2025 Mar 27. doi:...

Immune history shapes human antibody responses to H5N1 influenza viruses.

Garretson TA, Liu J, Li SH, Scher G, Santos JJS, Hogan G, Vieira MC, Furey C, Atkinson RK, Ye N, Ort JT, Kim K, Hernandez KA, Eilola T, Schultz DC, Cherry S, Cobey S, Hensley SE. Nat Med...

Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity.

Tursi NJ, Tiwari S, Bedanova N, Kannan T, Parzych E, Okba N, Liaw K, Sárközy A, Livingston C, Trullen MI, Gary EN, Vadovics M, Laenger N, Londregan J, Khan MS, Omo-Lamai S, Muramatsu H, Blatney K, Hojecki C, Machado V,...

The epigenetic landscape of fate decisions in T cells.

Jay A, Pondevida CM, Vahedi G. Nat Immunol. 2025 Mar 19. doi: 10.1038/s41590-025-02113-x. Online ahead of print. PMID: 40108419

B cell stimulation changes the structure and higher-order organization of the inactive X chromosome.

Sierra I, Toothacre NE, van der Weide RH, Lovell CD, Nguyen SC, Barnett RJ, Cook AL, Ryu HS, Pyfrom S, Wang H, Beiting D, Philips-Cremins JE, Joyce EF, Anguera MC. Cell Rep. 2025 Mar 25;44(3):115351. doi: 10.1016/j.celrep.2025.115351. Epub...

Bacteriocin production facilitates nosocomial emergence of vancomycin-resistant Enterococcus faecium.

Mills EG, Hewlett K, Smith AB, Griffith MP, Pless L, Sundermann AJ, Harrison LH, Zackular JP, Van Tyne D. Nat Microbiol. 2025 Mar 21. doi: 10.1038/s41564-025-01958-0. Online ahead of print. PMID: 40119148

A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.

Fiore D, Cappelli LV, Zhaoqi L, Kotlov N, Sorokina M, Phillip J, Zumbo P, Yoffe L, Ghione P, Wang A, Han X, Taylor A, Chiu W, Fragliasso V, Tabbo F, Zamponi N, Di Siervi N, Kayembe C, Medico G, Patel...

Targeting pathogenic interferon-stimulated gene RSAD2 improves pregnancy outcomes in systemic lupus erythematosus models.

Negatu SG, Jurado KA. Cell Rep Med. 2025 Mar 18;6(3):102034. doi: 10.1016/j.xcrm.2025.102034. PMID: 40107239

Therapeutic activation of IL-22-producing innate lymphoid cells enhances host defenses to Clostridioides difficile infection.

Mears KS, Denny JE, Maslanka JR, Mdluli NV, Hulit EN, Matsuda R, Furth EE, Buffie CG, Abt MC. Cell Rep. 2025 Mar 25;44(4):115438. doi: 10.1016/j.celrep.2025.115438. Online ahead of print. PMID: 40138315

CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial.

Reiss KA, Angelos MG, Dees EC, Yuan Y, Ueno NT, Pohlmann PR, Johnson ML, Chao J, Shestova O, Serody JS, Schmierer M, Kremp M, Ball M, Qureshi R, Schott BH, Sonawane P, DeLong SC, Christiano M, Swaby RF, Abramson S,...

Deucravacitinib Improves Cutaneous Lupus Erythematosus Activity

Victoria Werth, MD, a professor of Dermatology, investigated repurposing a currently FDA-approved medication to treat cutaneous lupus erythematosus (CLE), an autoimmune disease. The study, a phase 2 trial of the drug deucravacitinib already in use and approved to reduce...

American Association for Cancer Research Honors Oncology Leaders

Distinguished cancer researchers Garrett M. Brodeur, MD, Susan Domchek, MD, Stephan Grupp, MD, PhD, and Robert Vonderheide, MD, DPhil, from the Perelman School of Medicine and the Abramson Cancer Center have been elected to the 2025...

Purified T Cell Transplant Lowers Risk of Immune Reaction in Blood Cancer Patients

An experimental T cell therapy significantly reduced the risk of a debilitating immune reaction called chronic graft versus host disease in patients with several types of blood cancer. It’s one of the first examples of successfully engineering bone marrow grafts...

H5N1 Immune Response Correlates with Birth Year

New research from Scott Hensley, PhD, a professor of Microbiology, suggests that younger populations could gain more from vaccination efforts if an H5N1 outbreak were to emerge. The study reveals that immunity to H5N1 may hinge on the year...